Introduction {#s1}
============

The term CITRIN was designated in 1999 to stand for the protein product encoded by *SLC25A13* gene, which was localized to chromosome 7q21.3 and cloned as the causative gene for Adult-onset Citrullinemia Type 2 (CTLN2, OMIM \#603471) [@pone.0074544-Kobayashi1]. *SLC25A13* mutations result in citrin deficiency (CD), and CTLN2 was the firstly-described CD phenotype, which occurs in adolescents or adults and the prognosis is usually not benign [@pone.0074544-Kobayashi2]. Subsequently, CD was found to be associated with intrahepatic cholestasis in neonates or infants [@pone.0074544-Ohura1]--[@pone.0074544-Tomomasa1], and these findings led to the introduction of a new nomenclature of Neonatal Intrahepatic Cholestasis caused by Citrin Deficiency (NICCD, OMIM \#605814) [@pone.0074544-Saheki1]--[@pone.0074544-Yamaguchi1]. NICCD usually demonstrates satisfactory clinical outcomes, with the clinical and laboratory presentations resolving in the first year of life. It has been traditionally-assumed for years that there is a "silent" or "apparently-healthy" stage after the NICCD period but before CTLN2 onset. However, this concept has been challenged by accumulating clinical, laboratory and even behavioral evidences [@pone.0074544-Nagasaka1]--[@pone.0074544-Okano1], and actually, an additional CD phenotype, Failure to Thrive and Dyslipidemia caused by Citrin Deficiency (FTTDCD), has been put forward recently [@pone.0074544-Kobayashi2], [@pone.0074544-Saheki3]--[@pone.0074544-Zhang1].

The phenotypic features of CD patients are really complicated indeed, involving numerous clinical, biochemical, imaging, hepatohistological and metabolomic alterations [@pone.0074544-Song1], [@pone.0074544-Ohura2]--[@pone.0074544-Kuhara1]. However, none of these changes are pathognomonic, and *SLC25A13* genetic analysis has been recognized as a reliable method for the definitive diagnosis of CD. In the case of unknown mutation after the conventional genetic analyses such as PCR-RFLP and direct DNA sequencing, detection of the protein and mRNA product of *SLC25A13* gene could be considered as the alternative diagnostic tools. However, cultured fibroblasts or biopsied/autopsied liver specimens are usually needed in such analyses [@pone.0074544-Kobayashi1], [@pone.0074544-BenShalom1]--[@pone.0074544-Fu1], and obtaining these invasive samples may not always be feasible. To address this issue, citrin protein analysis using peripheral blood lymphocytes (PBLs) had been tried [@pone.0074544-Tokuhara1]. More recently, it was proved that *SLC25A13* cDNA cloning analysis using human PBLs could be taken as a less invasive and more feasible tool to identify aberrant *SLC25A13* transcripts for the molecular diagnosis of CD [@pone.0074544-Zhang1]. However, more experience should be accumulated on the application of this new approach in identifying unknown *SLC25A13* mutations.

Owing to the establishment of the molecular diagnostic tools, increasing number of CD patients were diagnosed in Asia [@pone.0074544-Luder1]--[@pone.0074544-Wongkittichote1], North America [@pone.0074544-Dimmock1], [@pone.0074544-Dimmock2], [@pone.0074544-Wong1], and Europe [@pone.0074544-Hutchin1]--[@pone.0074544-Fiermonte1]. Nevertheless, up to now, the majority of the reported CD patients were from East Asian countries, especially Japan [@pone.0074544-Kobayashi1], [@pone.0074544-Ohura1]--[@pone.0074544-Tomomasa1], [@pone.0074544-Yamaguchi1], [@pone.0074544-Nagasaka1], [@pone.0074544-Okano1], [@pone.0074544-Ohura2], [@pone.0074544-Komatsu1], [@pone.0074544-Tabata1], [@pone.0074544-Tokuhara1], [@pone.0074544-Yasuda1]--[@pone.0074544-Takahashi1]. China is a vast country with a huge population. According to the latest official data (<http://www.chinapop.gov.cn/xwzx/rkxw/>), the resident population in China is more than 1.3 billion, with 472 millions of them in the south area of Yangtze River. The carrier rates of *SLC25A13* mutations had been documented to be 1/63 in China, and particularly 1/48 in its south area [@pone.0074544-Lu1], [@pone.0074544-Kobayashi3]. Therefore, if calculated according to Hardy-Weinberg principle, the number of CD patients in China would be approximately 85 700, over 51 300 of whom are living in the South China. However, the officially-reported CD patients from China, including those from the south, were rather limited in number [@pone.0074544-Song1], [@pone.0074544-Zhang1], [@pone.0074544-Song2], [@pone.0074544-Fu1], [@pone.0074544-Xing1], [@pone.0074544-Wen1], [@pone.0074544-Lin2], and the distribution of *SLC25A13* mutations in Chinese patients remains far from being completely elucidated.

In this paper, novel *SLC25A13* mutations in 16 Asian CD patients were identified, including a large transposal insertion that gave rise to exon 5 skipping in *SLC25A13* transcripts. We established a large pediatric cohort of Chinese CD patients, and then explored the mutation spectrum and compared the distribution in different geographical areas. We herein reported the findings.

Subjects and Methods {#s2}
====================

Subjects {#s2a}
--------

The research subjects in this paper encompassed 68 new CD patients comprising 60 Chinese, 7 Japanese and 1 Malaysian. In order to explore the *SLC25A13* mutation spectrum and the distribution feature in different areas of China, 56 CD patients reported previously by our group were also enrolled in this paper to establish a large pediatric CD cohort.

Ethics Statement {#s2b}
----------------

This study has been approved by the Committee for Ethics of Kagoshima University Faculty of Medicine, Japan, and by the Medical Ethical Committee, the First Affiliated Hospital, Jinan University, China, and adheres to the World Medical Association Declaration of Helsinki (WMADH 2008), which was adopted by the 59th WMA General Assembly, Seoul, in October 2008. *SLC25A13* analyses were conducted with the written informed consents from the patients or their guardians.

Mutation Screening and Direct DNA Sequencing {#s2c}
--------------------------------------------

All patients were initially screened for the frequently recurring *SLC25A13* mutations. Thirteen *SLC25A13* mutations were included in the screening panel for the 7 Japanese patients in Kagoshima University, Japan, as in reference [@pone.0074544-Tabata1]. And, 4 mutations were screened in the remaining 61 novel subjects in Jinan University, China. In the subjects whose initial screening only revealed one mutated allele, the 18 exons and their flanking sequences in *SLC25A13* gene were analyzed by direct DNA sequencing, using the approach as described in our previous publications [@pone.0074544-Song1], [@pone.0074544-Zhang1], [@pone.0074544-Song2], [@pone.0074544-Lin2].

Pathogenicity Analysis of the Novel Mutations {#s2d}
---------------------------------------------

According to the HUGO mutation database initiative/Human Genome Variation Society (Instruction for Authors \[DB/OL\]. New Jersey (IL): John Wiley & Sons, Inc. 2008 \[2008-03-24\]. <http://www3.interscience.wiley.com/journal/38515/home/ForAuthors.html>), proof of pathogenicity in this study was defined by at least one of the following criteria: (1) a mutation presenting at the frequency of \<1% in at least 50 control individuals, (2) a mutation with co-segregation in a family; (3) alteration of an evolutionary conserved amino acid residue, and (4) nonsense and deletion variation in the coding sequence of *SLC25A13* gene. Moreover, the function effect of the novel missense mutations identified in this study was predicted with the software PolyPhen-2 at <http://genetics.bwh.harvard.edu/pph2/>, and a mutation is classified as "probably damaging" if its probabilistic score is above 0.85 while as "possibly damaging" with the score above 0.15 [@pone.0074544-Adzhubei1].

The frequency of 1 novel splice-site and 4 missense mutations in at least 50 control individuals was investigated by newly-developed PCR-RFLP approaches. The PCR primer pairs were Ex-4F: 5′-TGGACAGACCACAATTCATCAA-3′ and IVS5B:5′-GACGGAGTCTCGCTCTTTCA-3′, IVS5NF: 5′-TGAGGGCTTGTTAGATCAAGAT-3′ and IVS6NB:5′-TTACCCAGACAACAAATTAACCT-3′, IVS1NF:5′-TTTATGCACTGGGGCAACATG-3′ and Ex2Bm:5′-TGCTCTCTTGGTTAAAGCCAC[T]{.ul}-3′, IVS13F:5′-GGATGTCACAGGCAGAGTTC-3′ and IVS14B:5′-CTCATCTGCCAGAATGAAGATT-3′, and IVS10F:5′-GGACTGATGCGGCTGTTAGA-3′ and SLCE12A:5′-TGGTGAGTTCCCCTGCTTTC-3′. The restriction endonucleases (REs) used for the RFLP analyses were Hin1 II (Fermentas), BseNI (Fermentas), PsiI (New England Biolabs), Taq I (Fermentas) and Hae III (Takara) for RFLP analysis, respectively. And, the frequency of the remaining missense mutations was explored by using direct DNA sequencing due to the lack of REs for their PCR-RFLP analysis. If parental DNA samples were available in some families, mutation co-segregation analyses were conducted by the PCR-RFLP or DNA sequencing approach described above. Moreover, by using a comparative alignment software of Genetyx® version 7.1 (Genetyx company, Tokyo, Japan), the amino acid sequences of human citrin and aralar were aligned with those in the homologous proteins from 9 different eukaryotic species, including chimpanzee, dog, mouse, rat, chicken, xenopus tropicalis, caenorhabditis elegans, opossum and cow. The amino acid sequences for the proteins were collected from the database ENSEMBL at <http://www.ensembl.org/index.html>.

Total RNA Extraction and RT-nested PCR {#s2e}
--------------------------------------

In the patient C0054, only one paternally-inherited c.1399C\>T mutation was revealed by routine screening and direct sequencing. The maternally-inherited mutation was further explored by mRNA analysis. Extraction of the total RNA and RT-nested PCR were performed as previously described [@pone.0074544-Zhang1], [@pone.0074544-Lin2]. Briefly, PBLs were collected from heparinized venous blood of the patient, and the total RNA was extracted with RNAiso Plus (Takara). After that, 1 µg of RNA product was reverse-transcribed in the presence of 1 µg of oligo-(dT)18 and 200 U MMLV reverse transcriptase (Promega), and nested PCR was then performed with two pairs of primers, i.e. RAS2: 5′-AACGCACGCTGCCTGGCCGTATC-3′ and RACEA1: 5′-CCACCTTC ACAAATTCATGCGCC-3′ for the first PCR, while RAS3: 5′-GCCGCCGGGACTAGAAGTGAGC-3′ and Ex18R: 5′-TGCTTCATTCCCAGGAGGGA-3′ for the second. The amplicon contained the entire *SLC25A13* ORF, with a deduced size of 2191 bp.

cDNA Cloning Analysis {#s2f}
---------------------

After the mRNA extraction and RT-nested PCR, cDNA cloning was carried out in the patient C0054 to identify the aberrant mRNA molecule originated from the maternal allele that harbored an unknown mutation. In accord with the approach that was developed very recently [@pone.0074544-Zhang1], the nested PCR products were then separated by electrophoresis and the fragments of interest were excised and purified by gel extraction kit (Omega). Then the purified cDNA products were cloned into pSIMPLE-18 *Eco*R V/BAP Vector (Takara) and transformed into DH5α *Escherichia coli* competent cells by means of heat shock. The positive clones were screened by means of "white-blue spot selection" and tested by PCR with the primer pair RAS3 and Ex18R. The positive clones were then sequenced and comparatively aligned with the *SLC25A13* mRNA sequence. The alternative splicing variants (ASVs) identified by cDNA cloning analysis were described based on the nomenclature guidelines [@pone.0074544-denDunnen1]. Chi square test was adopted to compare the proportion difference of the ASVs in the patient C0054 and 8 healthy volunteers, with *P*\<0.05 as the significant criterion.

SNP Analysis {#s2g}
------------

The cDNA cloning analysis in the patient C0054 identified an aberrant transcript that was strongly suggestive of a large insertion/deletion mutation within the DNA fragment spanning from intron 4 to intron 5 in the *SLC25A13* gene. Subsequently, seven SNPs within this span, i.e. rs6465494(A/G), rs4727337(A/G) and rs67843496 (AA/−) in intron 4, and rs6943325(C/T), rs13307036(C/T), rs6465490 (C/A) and rs4273779(G/A) in intron 5, were analyzed by means of PCR amplification and direct sequencing. DNA fragments with heterozygous SNPs were not suspected to carry large insertion/deletion. On the contrary, if an amplicon was found with a homozygous SNP, a DNA fragment larger than the amplicon in size would be amplified by Long-range PCR (LA-PCR) using Takara LA Taq™ polymerase (Takara) according to the manufacturer's instructions. The product of unexpected size was excised, purified and sequenced to explicit the nature of the likely large insertion/deletion in the patient C0054. The large transposal insertion identified in this patient was then deposited in GenBank (Accession number: KF425758).

Update of the *SLC25A13* Mutations {#s2h}
----------------------------------

It was mainly by using Pubmed, the well-recognized information retrieval system that comprises more than 22 million citations for biomedical literature from MEDLINE, life science journals, and online books (<http://www.ncbi.nlm.nih.gov/pubmed/>), that we collected all the references on CD since the year 1999 when the *SLC25A13* gene was cloned. The *SLC25A13* mutations identified in CTLN2 or NICCD patients, including their locations, types, and the DNA, cDNA and amino acid changes were updated and listed into a table.

Mutation Spectrum in the Large Pediatric Cohort in China {#s2i}
--------------------------------------------------------

The genotypic and phenotypic features of 60 new NICCD patients in China were described in this study. These new patients, along with the 56 subjects reported previously by our group [@pone.0074544-Song1], [@pone.0074544-Zhang1], [@pone.0074544-Song2], [@pone.0074544-Lin2], [@pone.0074544-Zhao1], constituted a large Pediatric cohort of 116 CD patients in China. The *SLC25A13* mutation spectrum in this cohort was then summarized, and the proportion of every mutation in the whole spectrum was calculated and listed into a table. By using Chi square test and *P*\<0.05 as the significant criterion, the distribution feature of *SLC25A13* mutations in South and North China were compared, with the latitude of 30°N as the dividing line, the most likely boundary between northern and southern Chinese who originated from distinct ancestors [@pone.0074544-Lin3].

Results {#s3}
=======

Novel Point/Deletion Mutations {#s3a}
------------------------------

As shown in [Table 1](#pone-0074544-t001){ref-type="table"}, 15 novel mutations, including 9 missense (c.443A\>G, c.1498T\>G, c.527G\>T, c.1048G\>A, c.1063C\>G, c.415G\>A, c.1364G\>T, c.1215G\>T and c.1775A\>C), 4 nonsense (c.448G\>T, c.1736G\>A, c.1645C\>T and c.72T\>A), 1 splice-site (c.16-2A\>T) and 1 deletion (c.265delG), were identified by direct DNA sequencing analysis of the 18 exons and their flanking sequences in *SLC25A13* gene of the 15 CD patients in East Asia, everyone of whom harbored a previously-reported mutation that had been uncovered by routine mutation screening. [Figure S1](#pone.0074544.s001){ref-type="supplementary-material"} demonstrated the segmental sequencing results of the 15 mutations.

10.1371/journal.pone.0074544.t001

###### Fifteen novel mutations in the *SLC25A13* gene of citrin-deficient patients from different countries.

![](pone.0074544.t001){#pone-0074544-t001-1}

  Patient    Gender    Origin    Phenotype        SLC25A13 Genotypes             Effects           Frequency                   
  --------- -------- ---------- ----------- ------------------------------- ------------------ ------------------ ------------ ---------
  P111        Male     Japan       CTLN2       **c.448G\>T**/IVS11+1G\>A            --                 --           p.E150X       --
  P530        Male     Japan       NICCD      **c.1736G\>A**/IVS16ins3kb            --                 --           p.W579X       --
  P645       Female    Japan       CTLN2      **c.443A\>G**/c.851_854del            --                 --           p.Y148C     \<1%^△^
  P874       Female    Japan       NICCD      **c.1498T\>G**/IVS11+1G\>A      IVS11+1G\>A/N       c.1498T\>G/N      p.Y500D     \<1%^△^
  P917       Female    Japan       NICCD      **c.16-2A\>T**/IVS11+1G\>A      IVS11+1G\>A/N       c.16-2A\>T/N     IVS1-2A\>T   \<1%^△^
  P1075       Male     Japan       NICCD        **c.527G\>T**/c.674C\>A             --                 --           p.G176V     \<1%^△^
  P1508       Male     Japan       CTLN2       **c.1645C\>T**/c.674C\>A        c.674C\>A/N        c.1645C\>T/N      p.Q549X       --
  C0060       Male     China       NICCD        **c.72T\>A**/c.775C\>T         c.775C\>T/N         c.72A\>T/N        p.Y24X       --
  C0079       Male     China       NICCD      **c.1048G\>A**/IVS16ins3kb      IVS16ins3kb/N       c.1048G\>A/N      p.D350N     \<1%^▴^
  C0098       Male     China       NICCD     **c.1063C\>G**/c.1638_1660dup   c.1638_1660dup/N     c.1063C\>G/N      p.R355G     \<1%^▴^
  C0106       Male    Malaysia     NICCD       **c.415G\>A**/IVS16ins3kb            --                 --           p.G139R     \<1%^▴^
  C0108      Female    China       NICCD     **c.1364G\>T**/c.1638_1660dup     c.1364G\>T/N     c.1638_1660dup/N    p.R455L     \<1%^▴^
  C0157       Male     China       NICCD     **c.265delG**/c.1638_1660dup    c.1638_1660dup/N     c.265delG/N      p.D89fs94X     --
  C0168       Male     China       NICCD      **c.1215G\>T/**c.851_854del      c.1215G\>T/N      c.851_854del/N     p.K405N     \<1%^△^
  C0170      Female    China       NICCD      **c.1775A\>C/**c.851_854del     c.851_854del/N      c.1775A\>C/N      p.Q592P     \<1%^▴^

The bold black letters denote the novel mutations, "N" indicates the normal SLC25A13 allele, while "--" means not analyzed. The effects and frequency refer to the corresponding novel mutations. The frequency was calculated based on the screening result by PCR-RFLP (**^△^**) or direct DNA sequencing approach (^▴^), respectively.

Pathogenicity {#s3b}
-------------

The frequency of the missense and splice-site mutations were investigated in controls by the newly-developed PCR-RFLP, as illustrated in [Figure 1](#pone-0074544-g001){ref-type="fig"}, or sequencing approach, and all of them proved less than 1% ([Table 1](#pone-0074544-t001){ref-type="table"}). Moreover, on family linkage analysis, the novel mutations demonstrated different parental sources with the previously-reported mutations in the same family ([Table 1](#pone-0074544-t001){ref-type="table"}). In addition, comparative alignment of the homologous proteins in different eukaryotic species with human citrin and aralar further documented the conservative properties of the amino acids involved by the 9 missense mutations ([Figure 2](#pone-0074544-g002){ref-type="fig"}). And, on PolyPhen2 analysis of their function effect, Q592P was "possibly damaging" with a score 0.529 whilst the remaining 8 ones "probably damaging", all with the score above 0.99. These evidences documented that the novel splice-site/missense mutations identified in this study were all disease-causing.

![PCR-RFLP approaches for the carrier rate investigation of the 5 novel missense mutations.\
The figures to were representative gel electrophoresis of the RE-digested PCR products of the mutations c.443A\>G, c.527G\>T, c.16-2A\>T, c.1498T\>G and c.1215G\>T, while the figures to illustrated schematically the PCR-RFLP procedures for the 5 mutations, respectively. In , both the patient P917 and one of her brothers B1 harbored the maternally-inherited novel mutation c.16-2A\>T.](pone.0074544.g001){#pone-0074544-g001}

![Comparative alignment of the homologous proteins.\
The homologous proteins include human citrin (Homo sapiens) and aralar, and the others from 9 different eukaryotic species, i.e. Chimpanzee, Dog, Mouse, Rat, Chicken, Xenopus Tropicalis (X.Tropicalis), Caenorhabditis elegans (C. elegans), Opossum and Cow, respectively. The closed brown boxes in this figure represented the EF-hand or TM helices in citrin protein, as clarified in the reference by Kobayashi et al, 1999.](pone.0074544.g002){#pone-0074544-g002}

Results of cDNA Cloning Analysis {#s3c}
--------------------------------

The cDNA cloning analysis using PBLs in the patient C0054 uncovered a variety of ASVs from the maternally-inherited *SLC25A13* allele, and it was noteworthy that, as shown in [Table 2](#pone-0074544-t002){ref-type="table"}, 95.8% (23/24) of the ASVs demonstrated exon 5 skipping (r.329_468del). However, *SLC25A13* cDNA cloning analysis in 8 healthy volunteers documented that the ASV harboring *r*.329_468del only made up a proportion of 0.9% (1/116, as shown in [Table S1](#pone.0074544.s002){ref-type="supplementary-material"}). The difference between the two proportions proved significant, with χ^2^ = 119.7 and *P*\<0.01 ([Table S2](#pone.0074544.s003){ref-type="supplementary-material"}). The common feature of exon 5 skipping in the maternally-inherited ASVs in the patient C0054 indicated that the unknown mutation of maternal origin had affected the splicing mechanism around exon 5, strongly suggestive of a large insertion or deletion within the DNA segment spanning from intron 4 to intron 5 in the *SLC25A13* allele.

10.1371/journal.pone.0074544.t002

###### The *SLC25A13* ASVs detected by cDNA analysis in the patient C0054.

![](pone.0074544.t002){#pone-0074544-t002-2}

  Alleles                   Name                                         ASVs                                                                    Remarks                               Clones    \%
  ---------------------- ---------- ------------------------------------------------------------------------------- ----------------------------------------------------------------- -------- ------
  Maternally-inherited      M-01                                    *r*.213_468del                                                          Exon 4,5 skipping                            8      33.3
                            M-02                                     *r*.70_468del                                                         Exon 3,4,5 skipping                           4      16.7
                            M-03                           *r*.213_468del; *r*.1453_1591del                                               Exon 4,5,15 skipping                           3      12.5
                            M-04                                    *r*.329_468del                                                           Exon 5 skipping                             2      8.3
                            M-05                             *r*.16_69del; *r*.213_468del                                                  Exon 2,4,5 skipping                           1      4.2
                            M-06     *r*.70_468del; *r*.69_469ins212+6499_212+6611;*r*.1018_1019ins1018+1_1018+469   Exon 3,4,5 skipping with intron3 and intron10fragment retention     1      4.2
                            M-07                 *r*.70_468del; *r*.1452_1453ins1452+12639_1452+12773                     Exon 3,4,5 skipping with intron14 fragment retention           1      4.2
                            M-08                     *r*.70_468del; *r*.1750_1751ins1750+1_1750+93                             Exon 3,4,5 skipping with intron16 retention               1      4.2
                            M-09                            *r*.213_468del; *r*.755_848del                                                 Exon 4,5,8 skipping                           1      4.2
                            M-10                     *r*.213_468del; *r*.69_70ins69+12147_69+12282                          Exon 4,5 skipping with intron2 fragment retention            1      4.2
                            M-11                                    *r*.213_328del                                                           Exon 4 skipping                             1      4.2
                          In total                                        24                                                                       100                                         
  Paternally-inherited      P-01                             *r*.213_328del; *r*.1399C\>T                                                    Exon 4 skipping                             1      33.3
                            P-02                             *r*.213_468del; *r*.1399C\>T                                                   Exon 4,5 skipping                            1      33.3
                            P-03      *r*.213_328del;*r*.755_848del;*r*.1399C\>T; *r*.1750_1751ins1750+1_1750+93                Exon 4,8 skipping with intron16 retention                1      33.3
                          In total                                         3                                                                       100                                         

In this table, all the maternally-inherited ASVs but M-11 harbored *r*.329_468del. The nucleotide numbering was based on *SLC25A13* cDNA sequence (GenBank: NM_014251), with +1 indicating the A of the ATG-translation initiation codon.

Identification of a Large Transposal Insertion {#s3d}
----------------------------------------------

Based on the cDNA cloning results, SNPs analysis was performed within the above DNA span of interest. The SNPs rs6465494, rs4727337, rs6943325, rs13307036, rs6465490 and rs4273779, as illustrated in [Figure 3](#pone-0074544-g003){ref-type="fig"}, all demonstrated heterozygous status. However, rs67843496 was heterozygous in the PCR product amplified with the primers set A, but homozygous with set B. This finding led to the design of the primers set C, and LA-PCR amplification with this primer set yielded an unexpected product of 7.5 kb of maternal origin, which was proved by segmental sequencing to be a transposal insertion of 6072 bp in length (IVS4ins6 kb, GenBank accession number: KF425758), with two repetitive sequences of 15 bp on the both sides of a 6057 bp large insertion translocated from chromosome 16p11.2. One of the two repetitive sequences is the fixed DNA sequence within intron 4.

![Identification of the large transposal insertion IVS4ins6kb (GenBank accession number: KF425758).\
Seven SNPs within the introns 4 and 5 were analyzed, and all of them were heterozygous but rs67843496 (The schematic overhead), an SNP detected heterozygously when amplified by the primers set A () while homozygously with set B (). LA-PCR with the primers set C yielded an unexpected band of 7.5 kb inherited from the mother C0054M besides the expected 1439 bp product from the father C0054F (). Segmental sequencing of the 7.5 bp product revealed a 6057 bp insertion from 16p11.2 (The sequence in green) along with two repetitive sequences of 15 bp at both sides (Shaded boxes), as illustrated in . Underlined were the positions of the primers IVS5F and IVS5A4 (Set C) for LA-PCR.](pone.0074544.g003){#pone-0074544-g003}

Update of *SLC25A13* Mutations {#s3e}
------------------------------

To date, a total of 81 *SLC25A13* sequence variations in CD patients have been reported worldwide ([Table 3](#pone-0074544-t003){ref-type="table"}). The variations in the list demonstrated marked heterogeneity, comprising 32 missense (including 3 neutral), 18 nonsense, 14 splice-site (including c.1311C\>T), 9 deletion, 3 insertion, 2 duplication, 1 indel (g./c.1610--1612delTAGinsAT), 1 aberrant transcript (*r*.16_212dup) with unknown mutation, and 1 pathogenic SNP (c.2T\>C). Most (63%, 51/81) of the variations involved the C-terminal half of citrin protein that covers the 6 domains of transmembrane (TM) helices. In particular, 20 mutations were located within a DNA segment of 344 bp in size, spanning from exon 16 to exon 17 of the *SLC25A13* gene.

10.1371/journal.pone.0074544.t003

###### Update of *SLC25A13* mutations in patients with citrin deficiency.

![](pone.0074544.t003){#pone-0074544-t003-3}

  No.    Locations             Mutations                   Types              DNA/cDNA changes          Amino acids     References
  ----- ------------ ----------------------------- --------------------- --------------------------- ----------------- -------------
  1         Ex1                 c.2T\>C               Pathogenic SNP             g./c.2T\>C           p.Met1_Phe34del      14,34
  2         Ex1               g.Ex1-1G\>A               Splice-site              g./c.15G\>A              Unclear           22
  3         IVS1              IVS1-2A\>T                Splice-site              g.16-2A\>T               Unclear       This report
  4         Ex2                  E16X                    Nonsense                g./c.46G\>T              p.E16X            22
  5         Ex3                  Y24X                    Nonsense                g./c.72T\>A              p.Y24X        This report
  6         Ex3                 p.A25E                   Missense                g./c.74C\>A              p.A25E            21
  7         Ex3                 p.R43X                   Nonsense               g./c.127C\>T              p.R43X            21
  8         Ex3             c.172_173delGT               Deletion             g./c.172_173delGT         p.V58Gfs81X         21
  9      IVS2_IVS3    g./c.70-862_212+3527del4532        Deletion                c.70_212del              Unclear          20,35
  10       Ex2_3                Unknown             Aberrant transcript    r.16_212dup (Ex2_3dup)         Unclear           14
  11        Ex4                  L85P                    Missense               g./c.254T\>C              p.L85P            23
  12        Ex4                c.265delG                 Deletion               g./c.265delG            p.D89fs94X      This report
  13        IVS4              IVS4ins6kb                 Insertion          r.329_468del(Ex5 del)      p.E110fs127X     This report
  14        Ex5                  G139R                   Missense               g./c.415G\>A              p.G139R       This report
  15        Ex5                  Y148C                   Missense               g./c.443A\>G              p.Y148C       This report
  16        Ex5                  E150X                   Nonsense               g./c.448G\>T              p.E150X       This report
  17        Ex6                  Q159X                   Nonsense               g./c.475C\>T              p.Q159X           31
  18        Ex6                  G176V                   Missense               g./c.527G\>T              p.G176V       This report
  19        Ex6                  R184X                   Nonsense              g./(c.)550C\>T             p.R184X           44
  20        IVS6             g.IVS6+1G\>C               Splice-site          c.IVS6(1789 bp)ins        p.A206fs212X         44
  21        IVS6              IVS6+1G\>A                Splice-site            g./c.615+1G\>A             Unclear           23
  22        IVS6             g.IVS6+5G\>A               Splice-site          c\. not detectable           Unclear           44
  23        Ex7                  S225X                   Nonsense               g./c.674C\>A              p.S225X            1
  24        Ex7                Ex7-1G\>A                Splice-site       g./c.754G\>A/r.616_848del    p.A206fs213X         33
  25        IVS7              IVS7-2A\>G                Splice-site            g./c.755-2A\>G             Unclear           28
  26        Ex8                  Q259X                   Nonsense               g./c.775C\>T              p.Q259X           32
  27        Ex8                  G283X                   Nonsense               g./c.847G\>T              p.G283X           13
  28        IVS8             g.IVS8+3A\>C               Splice-site            g./c.848+3A\>C             Unclear           35
  29        Ex9                 851del4                  Deletion            g./c.851_854delGTAT       p.R284fs286X          1
  30        Ex9                Ex9-1G\>A                Splice-site               c.933G\>A               Unclear           16
  31        Ex10                 R319X                   Nonsense               g./c.955C\>T              p.R319X           28
  32        Ex10                 G333D                   Missense               g./c.998G\>A              p.G333D           17
  33        Ex11                 D350N                   Missense               g./c.1048G\>A             p.D350N       This report
  34        Ex11                 R355G                   Missense               g./c.1063C\>G             p.R355G       This report
  35        Ex11                p.R355X                  Nonsense               g./c.1063C\>T             p.R355X           21
  36        Ex11                 R360X                   Nonsense               g./c.1078C\>T             p.R360X           22
  37        Ex11             1092_1095delT               Deletion            g./c.1092_1095delT        p.F365fs407X         23
  38        Ex11               1146delA                  Deletion               g./c.1146delA          p.R383fs407X         22
  39        Ex11                 G386V                   Missense               g./c.1157G\>T             p.G386V           30
  40        Ex11                 G393S                   Missense              g./(c.)1177G\>A            p.G393S           27
  41       IVS11             g.IVS11+1G\>A              Splice-site            c.1019_1177del          p.340_392del          1
  42        Ex12                 Q397X                   Nonsense               g./c.1189C\>T             p.Q397X           26
  43        Ex12             1192-1193delT               Deletion            g./c.1192_1193delT        p.L398fs407X         30
  44        Ex12              c.1215G\>T                 Missense               g./c.1215G\>T             p.K405N       This report
  45        Ex13              c.1231G\>A                 Missense               g./c.1231G\>A             p.V411M           13
  46        Ex13                 G436E                   Missense         g./c.1307-1308delGCinsAA        p.G436E           38
  47        Ex13              c.1311C\>T               Splice-site?             g./c.1311C\>T             p.C437C           32
  48       IVS13             g.IVS13+1G\>A              Splice-site            c.1231_1311del          p.411_437del          1
  49       IVS13             g.IVS13+2T\>G              Splice-site          c\. not detectable           Unclear           22
  50        Ex14                 T446P                   Missense               g./c.1336A\>C             p.T446P           22
  51        Ex14                 K453R                   Missense               g./c.1358A\>G             p.K453R           30
  52        Ex14                 R455L                   Missense               g./c.1364G\>T             p.R455L       This report
  53        Ex14             1374_1375delG               Deletion           g./c.1374 or 1375delG      p.A459fs507X         22
  54        Ex14                 R467X                   Nonsense               g./c.1399C\>T             p.R467X           30
  55      IVS14_15             g.Ex15dup                Duplication            c.1453_1591dup          p.M532fs560X         19
  56        Ex15                 C489R                   Missense                g./c.T1465C              p.C489R           37
  57        Ex15                 D493G                   Missense               g./c.1478A\>G             p.D493G           43
  58        Ex15                 Y500D                   Missense               g./c.1498T\>G             p.Y500D       This report
  59        Ex15                 P502L                    Neutral               g./c.1505C\>T             p.P502L          32,34
  60       IVS15             g.IVS15+1G\>T              Splice-site            c.1453_1591del          p.G485fs491X         22
  61        Ex16                 Q549X                   Nonsense               g./c.1645C\>T             p.Q549X       This report
  62        Ex16                 W579X                   Nonsense               g./c.1736G\>A             p.W579X       This report
  63        Ex16                 G531D                   Missense                g.1592G\>A               p.G531D           22
  64        Ex16        c.1610_1612delTAGinsAT             Indel          g./c.1610_1612delTAGinsAT    p.L537fs538X         36
  65        Ex16                 A541D                   Missense               g./c.1622C\>A             p.A541D           28
  66        Ex16                p.T546R                  Missense               g./c.1637C\>G             p.T546R           21
  67        Ex16                 T546M                   Missense               g./c.1637C\>T             p.T546M           22
  68        Ex16               1638ins23                Duplication           g./c.1638_1660dup        p.A554fs570X          1
  69        Ex16                 R553Q                   Missense               g./c.1658G\>A             p.R553Q           31
  70     Ex16_IVS17    g.Ex16+74_IVS17-32del516          Deletion             c\. aberrant RNA         p.Q556fs565X         40
  71       IVS16             g.IVS16ins3kb               Insertion            c\. aberrant RNA         p.A584fs585X         22
  72        Ex17                 R588Q                   Missense               g./c.1763G\>A             p.R588Q           22
  73        Ex17                 L598R                   Missense               g./c.1793T\>G             p.L598R           25
  74        Ex17                 R585H                   Missense               g./c.1754G\>A             p.R585H           23
  75        Ex17                 Q592P                   Missense               g./c.1775A\>C             p.Q592P       This report
  76        Ex17               1800ins1                  Insertion           g./c.1799--1800insA          p.Y600X           39
  77        Ex17                 R605Q                    Neutral                c.1814G\>A               p.R605Q           34
  78        Ex17                 R605X                   Nonsense               g./c.1813C\>T             p.R605X           39
  79        Ex17                 E601X                   Nonsense              g./(c.)1801G\>T            p.E601X            8
  80        Ex17                 E601K                   Missense              g./(c.)1801G\>A            p.E601K            8
  81        Ex18                 P632L                    Neutral               g./c.1895C\>T             p.P632L          22,34

New Chinese Patients with NICCD {#s3f}
-------------------------------

We reported 60 new CD patients in this study ([Table 4](#pone-0074544-t004){ref-type="table"}). All the 60 novel cases presented with clinical features of NICCD at the point of referral to our hospital. During their most recent follow-up, the NICCD manifestations had improved in 22 patients below 1 year of age. Among the 38 subjects beyond 1 year of age, 11 cases were healthy, without any laboratory or clinical abnormalities. However, hepatomegaly was found in 1 patient, and anemia in 2 cases. Dyslipidemia was revealed in 7 cases while failure to thrive (FTT) in 3, and in particular, 5 patients had FTT and dyslipidemia concurrently, constituting 5 additional patients with FTTDCD features. The remaining 9 patients were lost in contact.

10.1371/journal.pone.0074544.t004

###### Molecular and clinical information of 60 new NICCD patients in China.
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  Case    Patient   Gender           Mutations               Major presentations                                  Clinical outcomes
  ------ --------- -------- --------------------------- ------------------------------ ------------------------------------------------------------------------
  57       C0049     Male         851del4/851del4                   NICCD                                            Dyslipidemia
  58       C0050    Female        851del4/851del4                   NICCD                                               FTTDCD
  59       C0054     Male        R467X/IVS4ins6kb                   NICCD                                            Dyslipidemia
  60       C0056     Male         851del4/851del4               NICCD, ASD+VSD                                      α-Thalassemia
  61       C0057     Male      851del4/1638-1660dup                 NICCD                                               Normal
  62       C0060     Male         Q259X/c.72A\>T                    NICCD                                            Dyslipidemia
  63       C0063     Male         851del4/851del4                   NICCD                                               FTTDCD
  64       C0068     Male         851del4/851del4                   NICCD                                            Dyslipidemia
  65       C0069     Male       851del4/IVS6+5G\>A                  NICCD                                            Lost contact
  66       C0070    Female        851del4/851del4                   NICCD                                            Lost contact
  67       C0071    Female        851del4/851del4                   NICCD                                            Dyslipidemia
  68       C0073    Female        851del4/851del4                   NICCD                                            Lost contact
  69       C0075    Female        851del4/851del4                   NICCD                                            Lost contact
  70       C0076    Female     851del4/1638-1660dup                 NICCD                                               FTTDCD
  71       C0078     Male         851del4/851del4                   NICCD                                               Normal
  72       C0079     Male     IVS16ins3kb/c.1048G\>A                NICCD                                            Lost contact
  73       C0082     Male    1638-1660dup/1638-1660dup              NICCD                                            Lost contact
  74       C0086     Male         851del4/851del4                   NICCD                                            Lost contact
  75       C0087     Male      851del4/1638-1660dup                 NICCD                                            Dyslipidemia
  76       C0095     Male       851del4/IVS6+5G\>A                  NICCD                                               Normal
  77       C0097     Male         851del4/851del4                   NICCD                                            Hepatomegaly
  78       C0098     Male     1638-1660dup/c.1063C\>G               NICCD                                            Lost contact
  79       C0099    Memale      851del4/IVS6+5G\>A                  NICCD                                               Normal
  80       C0108    Female    1638-1660dup/c.1364G\>T               NICCD                                               Normal
  81       C0109     Male         851del4/851del4                   NICCD                                               Normal
  82       C0110    Female       IVS6+5G\>A/R319X                   NICCD                                               Normal
  83       C0116     Male     IVS6+5G\>A/IVS16ins3kb                NICCD                                               Normal
  84       C0123    Female      851del4/IVS16ins3kb         NICCD, liver cirrhosis                 FTTDCD, ascites, umbilical hernia, Hematochezia
  85       C0124     Male          IVS6+5G\>A/?                 NICCD, eczema                                           Normal
  86       C0125     Male           Q159X/R467X                     NICCD                                            Dyslipidemia
  87       C0129     Male       851del4/IVS6+5G\>A          NICCD, liver cirrhosis        FTTDCD, Died of liver cirrhosis at his age of 2 years and 5 months
  88       C0130     Male         851del4/851del4        NICCD, Iron-deficient anemia                           Iron-deficient anemia
  89       C0134     Male       851del4/IVS6+5G\>A          NICCD, cerebral palsy                            FTT, improved cerebral palsy
  90       C0136    Female         851del4/R467X                    NICCD                                               Normal
  91       C0139    Female    1092-1095delT/c.754G\>A               NICCD                                                FTT
  92      C0139B     Male     1092-1095delT/c.754G\>A               NICCD                                               Normal
  93       C0140    Female    IVS11+1G\>A/IVS16ins3kb               NICCD                                        Improved cholestasis
  94       C0142    Female        851del4/851del4                   NICCD                                        Improved cholestasis
  95       C0143     Male         851del4/851del4                   NICCD                                        Improved cholestasis
  96       C0144    Female        851del4/851del4                   NICCD                                               Normal
  97       C0146     Male     IVS16ins3kb/IVS16ins3kb               NICCD                                                FTT
  98       C0147     Male      1638ins23/IVS6+5G\>A                 NICCD                                        Improved cholestasis
  99      C0068S    Female        851del4/851del4                   NICCD                                            Lost contact
  100      C0148    Female        851del4/851del4                   NICCD                                        Improved cholestasis
  101      C0149    Female        851del4/851del4                   NICCD                                        Improved cholestasis
  102      C0150     Male        IVS6+5G\>A/R319X                   NICCD                                        Improved cholestasis
  103      C0151    Female           851del4/?                      NICCD                                        Improved cholestasis
  104      C0154    Female        851del4/851del4                   NICCD                                        Improved cholestasis
  105      C0156    Female      851del4/IVS16ins3kb                 NICCD                                        Improved cholestasis
  106      C0157     Male       1638ins23/c.265delG                 NICCD                                  Improved cholestasis, hydrocele
  107      C0158    Female      851del4/IVS16ins3kb                 NICCD               Improved cholestasis, congenital muscular torticollis, inguinal hernia
  108      C0159     Male         851del4/851del4                   NICCD                                        Improved cholestasis
  109      C0160    Female      851del4/IVS16ins3kb                 NICCD                                        Improved cholestasis
  110      C0161    Female     851del4/1092-1095delT                NICCD                                        Improved cholestasis
  111      C0162    Female        851del4/851del4                   NICCD                                        Improved cholestasis
  112      C0163    Female        851del4/851del4                   NICCD                                        Improved cholestasis
  113      C0166     Male       1638ins23/1638ins23                 NICCD                                        Improved cholestasis
  114      C0168     Male       851del4/c.1215G\>T                  NICCD                                        Improved cholestasis
  115      C0169    Female           851del4/?                      NICCD                                        Improved cholestasis
  116      C0170    Female      851del4/c.1775A\>C                  NICCD                                        Improved cholestasis

Demographic Features of the Chinese Pediatric Cohort {#s3g}
----------------------------------------------------

So far, 116 Chinese CD patients have been diagnosed by our group. This pediatric cohort consisted of 48 females and 68 males, and involved 113 families from 21 provinces, municipalities and autonomous regions in China, including Guangdong, Guangxi, Hainan, Hunan, Hubei, Yunnan, Guizhou, Sichuan, Chongqing, Jiangxi, Fujian, Zhejiang, Jiangsu, Anhui, Shanghai, Henan, Hebei, Shandong, Liaoning, Jilin and Inner Mongolia. As shown in [Figure 4](#pone-0074544-g004){ref-type="fig"}, 93 out of the 116 patients were from South China, especially from Guangdong province (51 patients).

![Native places of the 116 Chinese patients with citrin deficiency.\
By the end of February in 2013, 116 Chinese patients from 21 provinces, municipalities and autonomous regions in China were diagnosed by *SLC25A13* gene analysis by our group. This figure indicated their native places, with the patient numbers in the parentheses behind.](pone.0074544.g004){#pone-0074544-g004}

The Distribution of *SLC25A13* Mutations in the Chinese Pediatric Cohort {#s3h}
------------------------------------------------------------------------

As shown in [Table 5](#pone-0074544-t005){ref-type="table"}, the 4 mutations 851_854del4, 1638_1660dup, IVS6+5G\>A and IVS16ins3kb were on the top of the list, and accounted for 83.19% of all mutated *SLC25A13* alleles, constituting the high-frequency mutations in this Chinese CD cohort. The remaining 22 mutations contributed 14.11%, whilst the unknown ones, just 2.7%. In South China, the 4 high-frequency mutations contributed 87.9% of the total mutated alleles, while this proportion in the North was just 63.6%, and this difference in the mutation distribution between the two areas in China was proved to be statistically significant, with χ^2^ = 14.93 and *P*\<0.01, as shown in [Table S3](#pone.0074544.s004){ref-type="supplementary-material"}.

10.1371/journal.pone.0074544.t005

###### Frequency and proportion of the mutated *SLC25A13* alleles in the large Chinese Pediatric cohort.
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  No.                      Mutations                 Frequency   Percentage
  ---------- -------------------------------------- ----------- ------------
  01                      851_854del4                   132        58.41
  02                      1638-1660dup                  20          8.85
  03                       IVS6+5G\>A                   19          8.41
  04                      IVS16ins3kb                   17          7.52
  05                   c.1399C\>T(R467X)                 5          2.21
  06                    c.955C\>T(R319X)                 3          1.33
  07                      IVS11+1G\>A                    3          1.33
  08                       c.754G\>A                     2          0.88
  09                    c.1092_1095delT                  2          0.88
  10                   c.1078C\>T(R360X)                 1          0.44
  11                   c.1622C\>A(A541D)                 1          0.44
  12                   c.1231G\>A(V411M)                 1          0.44
  13                    c.847G\>T(G283X)                 1          0.44
  14                    c.998G\>A(G333D)                 1          0.44
  15                    c.475C\>T(Q159X)                 1          0.44
  16                    c.775C\>T(Q259X)                 1          0.44
  17                        g.2T\>C                      1          0.44
  18                      r.16-212dup                    1          0.44
  19                     c.72T\>A(Y24X)                  1          0.44
  20                   c.1048G\>A(D350N)                 1          0.44
  21                   c.1063C\>G(R355G)                 1          0.44
  22                   c.1364G\>T(R455L)                 1          0.44
  23                       IVS4ins6kb                    1          0.44
  24                   c.1215G\>T(K405N)                 1          0.44
  25                       c.265delG                     1          0.44
  26                   c.1775A\>C(Q592P)                 1          0.44
  27                        Unknown                      6          2.7
  In total    226[\*](#nt103){ref-type="table-fn"}      100     

Among the 116 patients, there were 3 siblings from 3 families. Therefore, the cohort comprised 226 mutated *SLC25A13* alleles in total, including 6 unknown ones.

Discussion {#s4}
==========

Since *SLC25A13* was cloned as the causative gene for CD [@pone.0074544-Kobayashi1], genetic analysis of this gene had been well-recognized as a reliable tool for the definitive diagnosis of CD patients. By direct DNA sequencing, 15 novel *SLC25A13* variations were identified in this paper ([Table 1](#pone-0074544-t001){ref-type="table"} and [Figure S1](#pone.0074544.s001){ref-type="supplementary-material"}), and all of them proved to be CD-associated pathogenic mutations by laboratory and bioinformatic evidences ([Table 1](#pone-0074544-t001){ref-type="table"} and [Figures 1](#pone-0074544-g001){ref-type="fig"} and [2](#pone-0074544-g002){ref-type="fig"}). These novel mutations expanded the *SLC25A13* mutation spectrum, and provided conclusive genetic evidences for the definitive diagnosis of the East Asian patients, along with the mutations revealed at screening analysis. However, routine DNA analytic approaches such as PCR-RFLP and sequencing could not identify all *SLC25A13* mutations [@pone.0074544-Song1], [@pone.0074544-Tokuhara1], [@pone.0074544-Lu1], and the patient C0054 in this paper was such a case, in whom a paternally-inherited c.1399C\>T mutation was revealed by screening and direct sequencing, while the mutation of maternal origin once remained obscure on such routine DNA analytic tools.

Our recent cDNA cloning analysis of *SLC25A13* ASVs in human PBLs uncovered the marked transcript diversity along with the abundant existence of the transcript *r*.213_328del that predicted the existence of a constructively novel isoform for citrin protein. Similar ASVs could be detected for mutated *SLC25A13* alleles, but all of them carried the information of/from their corresponsive mutations [@pone.0074544-Zhang1]. *SLC25A13* cDNA analysis in this study ([Table 2](#pone-0074544-t002){ref-type="table"} and [Table S1](#pone.0074544.s002){ref-type="supplementary-material"}) confirmed our previous findings, and particularly, the unique feature of exon 5 skipping in the ASVs of maternal origin in the patient C0054 ([Table S2](#pone.0074544.s003){ref-type="supplementary-material"}) provided a reliable evidence for the positioning of a large insertion, or deletion, within the *SLC25A13* gene segment spanning from intron 4 to intron 5, and directly led to the final identification of the novel transposal insertion of IVS4ins6kb. These findings once again supported the concept that cDNA cloning analysis of *SLC25A13* gene using human PBLs could be taken as a feasible tool for the molecular diagnosis of citrin deficiency, overcoming the technical limitation of the conventional DNA analysis.

The large IVS4ins6kb mutation in this study is the second transposal insertion besides the one reported in 2008 [@pone.0074544-Tabata1]. This large insertion was identical in sequence to a DNA segment of 6057bp at chromosome 16p11.2, with two 15bp repetitive sequences on the both sides as the target-site duplication for this DNA transposon ([Figure 3](#pone-0074544-g003){ref-type="fig"}). We have no direct evidences yet to clarify the pathogenic mechanism underlying this transposal insertion. However, since IVS4ins6kb occurred very closely to the branch point site within intron 4, a reasonable explanation might be that the large insertion interrupted the formation of the lariat structure and thus disrupted the excision of intron 4 during the splicing reaction. However, this transposal insertion did not affect the branch point site within intron 5, and the freed 5′ end of intron 4 thus had to joined to this site alternatively, forming a lariat and giving rise to exon 5 skipping in the *SLC25A13* transcripts, as revealed by cDNA cloning analysis using PBLs in the patient C0054 ([Table 2](#pone-0074544-t002){ref-type="table"}). The exon 5 skipping predictively resulted in a frameshift at codon 110, added 17 amino acids, and then introduced a stop codon at position 127, thus yielding a truncated citrin molecule p.E110fs127X.

To the best of our knowledge, [Table 3](#pone-0074544-t003){ref-type="table"} was the most comprehensive update of the reported *SLC25A13* variations up to now, and the heterogenetic variations in this table constituted reliable molecular evidences for the definitive diagnosis of CD patients. However, it should be recognized that the list itself remained far from being perfect currently. One issue was the unclear mechanisms underlining specific mutations. For example, c.1311C\>T had been reported as a synonymous mutation p.C437C [@pone.0074544-Wen1], but this C\>T substitution might cause abnormal splicing of pre-mRNA since it involved the last base of the exon 13 in *SLC25A13* gene. Another issue lied in the limited experience on citrin protein analysis. Although the aberrant transcript *r*.16_212dup had been identified in a NICCD patient [@pone.0074544-Zhang1], its biochemical and structural effects on citrin protein remained obscure due to the technical limitation. The pathogenicity of some missense mutations was another issue. Actually, AGC2 function analysis had documented that c.1505C\>T, c.1814G\>A and c.1895C\>T were all neutral, but not missense mutations [@pone.0074544-Wongkittichote1]. The above issues once again necessitated the in-depth molecular analysis of CD by means of not only genetic, but also transcriptional, translational, and even functional tools.

Although the number of reported Chinese CD patients was relatively small, as a country with a population over 1.3 billion, China might be the largest victim of CD, currently having about 85 700 of such patients theoretically. We reported 60 new NICCD patients in this study ([Table 4](#pone-0074544-t004){ref-type="table"}), and thus established a Pediatric cohort of 116 CD cases, providing a foundation for the in-depth investigation of this disease entity in China. In the *SLC25A13* mutation spectrum, as shown in [Table 5](#pone-0074544-t005){ref-type="table"}, 851_854del4, 1638_1660dup, IVS6+5G\>A and IVS16ins3kb could be considered as high-frequency mutations in China while the remaining 22 mutations are mostly sporadic. This finding provided an important evidence for the screening of targeted *SLC25A13* mutations in Chinese population. The native place analysis of the CD patients in [Figure 4](#pone-0074544-g004){ref-type="fig"} uncovered that most patients are originated from south China, which could be explained partially by the higher carrier rate of *SLC25A13* mutations in this area than in the north [@pone.0074544-Lu1]. The geographic location of our hospital might be another likely reason. As the capital city of Guangdong province, Guangzhou was the largest city in South China.

The *SLC25A13* mutations were distributed differently in the patients from different areas in China, and as shown in [Table S3](#pone.0074544.s004){ref-type="supplementary-material"}, the 4 high-frequency mutations were more common in southern Chinese than in northern. This distribution difference might be attributed to the founder effect and genetic drift. The 4 high-frequency mutations had occurred earlier in southern Chinese during the long history of human evolution, and then dispersed into northern Chinese along with the population migration. Actually, haplotype analysis has proved that the mutation 851_854 del arose in the southern mongoloid population [@pone.0074544-Lu1], who originated in the Guangxi and Yunnan areas in the southwest China [@pone.0074544-Matsumoto1]. On the other hand, it has been proposed that the contemporary northern and southern Chinese have distinct origin site in the Yellow River valley and the Yangtze River valley, respectively, with the most likely boundary drawn at the latitude of 30°N [@pone.0074544-Zhao2], and anthropologic evidences have suggested that, in the early Middle Pleistocene, the early man in south of the Yangtze River dispersed to the Qinling Mountain and south of the Yellow River [@pone.0074544-Lin3].

In conclusion, the 16 novel pathogenic mutations identified in this study enriched the variation spectrum of *SLC25A13* gene, and the comprehensive update of *SLC25A13* mutations provided a reliable molecular evidence for the definitive diagnosis of CD patients. And, the establishment of the large Chinese Pediatric cohort, the *SLC25A13* mutations in this cohort, along with their distribution difference in the patients from different areas in China, formed a substantial contribution to the in-depth understanding of the genotypic features of Chinese CD patients.
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**Direct DNA sequencing results of the point and deletion mutations in** ***SLC25A13*** **gene.** In this study, 1 deletion and 14 point mutations of *SLC25A13* gene were identified in 15 patients with citrin deficiency. Arrows were used in this figure to indicate the mutated bases with description overhead, respectively.
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**The** ***SLC25A13*** **ASVs detected by cDNA analysis in eight healthy volunteers.**
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**Comparison of the** ***SLC25A13*** **ASVs harboring** ***r*** **.329_468del in the patient C0054 and the 8 healthy volunteers.**
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**Distribution of the mutated** ***SLC25A13*** **alleles in the CD patients from South and North China.**
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Click here for additional data file.
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